EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 173 filers reported holding EAGLE PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $927,152 | -49.6% | 47,693 | -26.5% | 0.00% | -100.0% |
Q1 2023 | $1,840,560 | +193.6% | 64,877 | +202.5% | 0.00% | – |
Q4 2022 | $626,896 | +11.7% | 21,447 | +69.9% | 0.00% | – |
Q2 2022 | $561,000 | +21.4% | 12,620 | +35.1% | 0.00% | – |
Q1 2022 | $462,000 | +18.2% | 9,342 | +21.5% | 0.00% | – |
Q4 2021 | $391,000 | +32.5% | 7,687 | +45.4% | 0.00% | – |
Q3 2021 | $295,000 | -19.8% | 5,288 | -33.1% | 0.00% | – |
Q4 2020 | $368,000 | -4.9% | 7,900 | -13.3% | 0.00% | – |
Q3 2020 | $387,000 | +82.5% | 9,114 | +126.7% | 0.00% | -100.0% |
Q1 2018 | $212,000 | -12.4% | 4,021 | +30.8% | 0.00% | 0.0% |
Q2 2017 | $242,000 | +10.0% | 3,073 | +15.8% | 0.00% | 0.0% |
Q1 2017 | $220,000 | -37.7% | 2,653 | -70.8% | 0.00% | -50.0% |
Q2 2016 | $353,000 | -56.7% | 9,100 | -54.8% | 0.00% | -50.0% |
Q1 2016 | $815,000 | +64.3% | 20,112 | +200.2% | 0.00% | +33.3% |
Q3 2015 | $496,000 | +15.1% | 6,699 | +25.8% | 0.00% | 0.0% |
Q2 2015 | $431,000 | +26.8% | 5,327 | -34.4% | 0.00% | 0.0% |
Q1 2015 | $340,000 | – | 8,125 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JW Asset Management, LLC | 475,755 | $25,068,000 | 24.71% |
Hudson Executive Capital LP | 971,000 | $51,162,000 | 15.09% |
Park West Asset Management LLC | 1,051,274 | $55,392,000 | 2.47% |
U S GLOBAL INVESTORS INC | 19,200 | $1,012,000 | 0.62% |
Capital Impact Advisors, LLC | 26,317 | $1,387,000 | 0.57% |
CLARK ESTATES INC/NY | 56,278 | $2,965,000 | 0.47% |
IRIDIAN ASSET MANAGEMENT LLC/CT | 873,131 | $46,005,000 | 0.41% |
ProQuest Associates IV LLC | 6,777 | $357,000 | 0.41% |
Granite Investment Partners, LLC | 114,207 | $6,017,000 | 0.40% |
GLOBEFLEX CAPITAL L P | 30,900 | $1,628,000 | 0.34% |